Pharvaris’ deucrictibant has tasted success in a second phase 3 study, strengthening the case for the therapy to treat ...

A pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the ...

Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival (PFS) demonstrated by its OX40 agonist ...

Clinical trials have become more complex, longer, and data-intensive. But the way many clinical-development decisions are ...

Boston Scientific has issued another recall, this time for its spinal cord implant used to treat pain. | Boston Scientific ...

A startup spawned from Seattle Children’s Hospital has raised a $116 million series A round to advance cell therapies for devastating childhood brain tumors. | A startup spawned from Seattle ...

Roivant’s $14 million bet on a pulmonary hypertension drug from Bayer appears to have paid off as the inhaled med aced a phase 2 lung disease study. | Roivant’s $14 million bet on a pulmonary ...

Novo Nordisk has given up on two more phase 3 trials of ziltivekimab, further eroding the prospects for a molecule that ...

ADARx Pharmaceuticals has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing ...

Novartis’ Ionis-partnered drug designed to lower levels of Lp (a), a known cardiovascular risk factor, failed to reduce patients’ risk of a heart attack, stroke, or other major cardiovascular events ...

Novartis has struck a deal worth up to $3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and ...

Ultragenyx had been flying high after its recent FDA approval for Genglycos—but the company has been brought back down to ...